Overview
Germany dialysis provider's Q4 revenue beat analyst expectations
Operating income for FY 2025 reached the upper end of financial outlook
Company announced EUR 1 bln share buyback program
Outlook
Fresenius Medical expects 2026 revenue growth to be broadly flat compared to prior year
Company forecasts 2026 operating income growth between positive and negative mid-single digits
Fresenius Medical aims for 3-7% CAGR operating income growth from 2025 to 2028
Result Drivers
EFFICIENCY GAINS - Fresenius Medical Care attributed its profitability increase to efficiency gains from the FME25+ program and favorable reimbursement developments
PORTFOLIO OPTIMIZATION - Divestitures as part of the portfolio optimization plan negatively impacted revenue by EUR 244 mln in 2025
SHARE BUYBACK - Accelerated share buyback program supported EPS growth
Company press release: ID:nPn2FVZ3ka
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
EUR 5.07 bln
EUR 4.84 bln (7 Analysts)
Q4 Net Income
EUR 327 mln
Q4 Basic EPS
EUR 1.14
Q4 EBIT
EUR 594 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 8 "hold" and 7 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fresenius Medical Care AG is €47.00, about 13.6% above its February 23 closing price of €41.39
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)